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The generation of quality data in biomedical research is dependent on 
utilisation of high-quality specimens. Although scientific publi cations 
overflow with research results and mounds of data, not necessarily all 
bring useful results. As stated by the US National Cancer Institute (NCI), 
the lack of standardised high-quality biospecimens is the cause of the 
lack in progress in cancer research.[1] High-quality research material 
and matching clinical data are also essential to comply with growing 
international requirements from regulatory authorities and funding 
agencies that biospecimens should be handled according to best practices. 
The latter include appropriately qualified staff who operate in a facility 
that can demonstrate high-quality management of research specimens 
pertaining to conditions of sample collection, preparation, storage and 
transportation, secure record-keeping, processes that regulate access to 
and utilisation of biospecimens, long-term sustainability strategies, and 
compliance with ethical and legal requirements.[2]
After collection, specimens for research are usually stored until 
they are needed. Ubiquitous in most research laboratories is the 
–80˚C freezer, loaded with saved specimens from one or more 
investigators. However, in view of the globally expanding drive 
for population-based and evidence-based research, access to and 
utilisation of biospecimens in this familiar environment are growing 
to the scale of requiring a biobank/biorepository.
A biobank is defined as an entity that acquires, preserves, develops 
and distributes biological specimens along with information, 
technology, intellectual property, and standards for the advancement 
and application of scientific knowledge.[3] Biobanks operated 
under best practices are important partners to translational health 
researchers, as they ensure high-quality specimens for their studies 
and employ functions and policies to ensure not only sound ethics 
but also quality through technical standards and operational 
practices. Additionally, some countries have legislation[4] covering the 
collection and use of human specimens in research. Governmental 
agencies and professional organisations such as the International 
Society for Environmental and Biological Resources (ISBER) produce 
standards to set a benchmark for quality.[5,6]
Variations in biobanks exist. Biobanks can be devoted to the 
collection of human specimens (e.g. tissues, DNA/RNA, blood, 
sperm) or animal, plant (e.g. seeds), microbial and environmental 
specimens. The biobank’s mission determines its scope and size. 
For example, biobanks related to human research can support basic 
science, translational science or clinical research. Biobanks vary in 
their size and in the type of specimens they store, and in the case 
of human biobanks, according to whether the specimens are from 
healthy individuals or from individuals with disease. Specimens can 
be banked from a single research project or represent diverse research 
areas.
The structure of a biobank can take numerous forms. If a bank 
is traditional, it holds specimens and data that are stored centrally. 
A procurement biobank collects specimens to meet a specific need, 
and may only have a limited data set. Virtual biobanks have multiple 
collection locations but a central location for the storage of data. A 
fully virtual/distribution bank has data and multiple collections and 
storage sites.[7]
The AIDS and Cancer Specimen Resource (ACSR), in existence 
since 1994, operates under a cooperative agreement between the 
NCI and various institutions. Its mandate is to collect and preserve 
tissues and biological fluids along with clinical data from patients with 
HIV-related malignant tumours and normal controls, which will be 
dispersed to qualified investigators.[8,9] The ACSR recently expanded 
its scope to include a regional biorepository to serve sub-Saharan 
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Africa (SSA RBR), located in the Division of Anatomical Pathology, 
National Health Laboratory Service (NHLS), Tygerberg Academic 
Hospital and Faculty of Medicine and Health Sciences, Stellenbosch 
University (Cape Town, South Africa (SA)). Under the auspices of the 
ACSR, the SSA RBR aims to proactively obtain, manage and process 
biospecimens (tissues, body fluids and derivatives, such as DNA and 
RNA) representing both AIDS-defining cancers (i.e. Kaposi’s sarcoma, 
non-Hodgkin’s lymphoma, cervical cancer) and non-AIDS-defining 
cancers (e.g. lung cancer, breast cancer, colon cancer) and associated 
clinical data (e.g. date of diagnosis, site of biopsy, antiretroviral 
and cancer therapies, CD4 counts). Ethics approval was secured 
and regulatory aspects ensured for specimen movement within the 
continent. Additional aims include the provision of information and 
training related to biobanking for African researchers and scientists, 
and the establishment of a community advisory board and community 
outreach portal to educate and to inform the public about the benefits 
and implications of biobanking for the health of African populations.
The SSA RBR also hosts the AIDS Malignancy Consortium (AMC) 
biorepository for support of its clinical trial activities in SSA. The 
AMC[10] supports innovative clinical trials for optimising treatment 
and prevention of AIDS-related cancers. The AMC was established 
in 1995 to perform domestic studies in the USA. In the past 5 
years the AMC widened its scope to conduct trials in international 
settings, particularly in SSA. The SSA RBR supports the biorepository 
requirements for AMC clinical trials performed on the African 
continent. This function involves receiving and storage of specimens 
under controlled conditions before sending them to specified core 
laboratories in Africa and globally. The process of establishing a 
biobank to fulfil both the ACSR and AMC mandates is described.
Developing the biobanking concept
Acceptance of biobanks to support research in SA and other African 
countries cannot be automatically assumed. One must be sensitive 
to past infringements of ethicoregulatory standards by international 
researchers, where many Africans repeatedly witnessed biological 
specimens leaving the continent to other countries[11] for research 
with no clear benefit to the African communities.
Scientifically and technologically, establishing the biobank was 
not a concern, but various concepts covered by the NCI and ISBER 
best practices were new and required adequate time to be adopted. 
Concomitantly, it was essential that this new site would relate to 
the ACSR mission ‘to acquire, store, and equitably distribute tumor 
tissues, biological fluids, and other biospecimens and associated 
clinical information from patients with HIV-associated malignancies 
to the scientific research community-at-large’. The concept and scope 
of the biobank were easily accepted, particularly since the prevalence 
of HIV/AIDS in SA is one of the highest in the world.
The biobank’s location in the immediate proximity of the laboratories 
of the Division of Anatomical Pathology at Tygerberg Academic 
Hospital facilitated the identification of qualified individuals who 
supported the establishment of the RBR infrastructure, and adoption 
of the manual of operations, standard operating procedures and 
bioinformatics platform of the ACSR. Besides discussions related 
to laboratory procedures for biobanks, and of the importance 
of preanalytical variables and controlling for them on research 
specimens,[12,13] selected best practices identified for more in-depth 
exploration are presented below.
Organisation, management and 
governance
Stellenbosch University, the site chosen for the new AMC/ACSR 
SSA biorepository, already had in-house repositories holding 
research study specimens for storage and distribution. In the 
existing scenarios, all specimens in the respective repositories 
were obtained as part of approved research projects and controlled 
and managed by the respective study investigators. Stellenbosch 
University already had regulatory offices in place to handle entry 
and exit permits and material transfer agreements; consequently, 
the mission of the AMC biorepository fitted aptly with other 
established projects. In addition, most of the African countries 
involved with AMC trials were already research partners with 
Stellenbosch University.
What was new, however, was the ACSR mission of procuring 
specimens to be used by investigators at that institution as well as by 
individuals from outside the institution, outside SA, and even outside 
Africa. At this point, in-depth discussions occurred regarding: (i) the 
ACSR mission; (ii) the functions of the ACSR regional biorepositories; 
(iii) the governance of the ACSR; (iv) how the new SAA RBR would 
fit into the present ACSR; (v) the mechanism for investigators to 
request specimens; (vi) how the requests were reviewed; and (vii) 
distribution of biospecimens and information sets.
A specific challenge emerged in view of the mandate by the NCI to 
ensure that findings derived from its inventory would benefit Africa 
and assist in building capacity for research. The SSA RBR would be 
unique within the ACSR in that investigators desiring specimens 
from its collection would need to be African or collaborating with 
an African researcher. This mission required various discussions 
between individuals ranging from other ACSR directors and members 
of the Health Research Ethics Committee (HREC) to people working 
with regulatory issues, e.g. entry/exit permits and material transfer 
agreements.
The SSA RBR complies with the South African National Health 
Act 61 of 2003 and adheres to the Ethics in Health Research Principles, 
Processes and Structures, as published in 2015 by the SA National 
Department of Health. Following extensive discussions with relevant 
authorities, the SSA RBR obtained permission from the Department 
of Health in the Western Cape Province and support from the NHLS. 
The SSA RBR operates according to inspection criteria as determined 
and monitored by the inspector of anatomy from the Western Cape 
Department of Health. It conforms and contributes to evolving 
ethicoregulatory detail and policies on biobanking and biospecimen 
utilisation in SA, and will pursue similar involvement in other SSA 
countries.
Custodianship v. ownership
The ACSR’s mandate to collect specimens and make them available 
to any African or collaborating researcher approved through peer 
review was a new concept, and one requiring some discussion. A 
major discussion with the HREC revolved around Stellenbosch 
University’s role as the custodian of the specimen (i.e. the caretaker 
of the specimen that ensures the privacy of the donor, the integrity of 
the specimen and its associated data, and that use of both conforms to 
informed consent) rather than its role as owner of the specimen (that 
‘donates’ its specimen to research and can retract that permission 
at any time). Also needing clarification was concern regarding the 
return of data from successful investigators who performed research 
on the SSA RBR specimens. The ACSR encourages successful 
recipients of ACSR samples to share their findings with the ACSR to 
enrich the remaining specimens’ value. However, as the specimens 
are only used for research and not clinical decisions, the donor of 
a specimen is never notified about investigative findings; rather, 
investigators share and disseminate findings through published 
articles and presentations of research findings at scientific meetings, 
acknowledging the ACSR.
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Community awareness and 
involvement
The SSA RBR promotes ethical and equitable biobanking policies for 
community and public education regarding biobanking and its role 
and value in improving the health of people on the African continent. 
For this purpose, the SSA RBR has developed a marketing and 
promotion strategy that is based on established ACSR principles but 
specifically directed at various SA target groups. Briefly, the strategy 
includes regular sharing of information pertaining to the SSA RBR 
with clinicians, health authorities, the general public and selected 
SA and African researchers; close collaboration with established 
researchers with African involvement to explore recruitment of 
specimens from clinical trial patients, involvement of selected 
societies that are active in the field of HIV and cancer, co-operation 
with community advisory boards, and regular presentations at 
regional congresses are further components of the marketing and 
promotion strategy.
A further responsibility taken on by the ACSR and its role of 
custodianship is the reporting of data found by investigators utilising 
ACSR specimens. The ACSR lists publications by inventory users on 
its website (http://acsr.ucsf.edu). Specific to the SSA RBR is sharing of 
information and results through the SSA RBR Community Advisory 
Board. This group of individuals comprises lay people working 
within the fields of or living with either HIV or cancer. The SSA 
RBR will periodically present, in lay language, summaries of the 
proposed research and the findings from research performed on the 
specimens to the group. This is a work in progress, with emphasis 
on the appropriate level of presentation of information to facilitate 
comprehension.
Discussion
The interval from award to launch of the SSA RBR was 14 months. 
The approach involved taking small steps at a time, with different 
levels of involvement from the administration, the faculty and the 
principal staff as necessary. Long-range plans include bringing 
in specimens from other sites in the Western and Eastern Cape 
provinces, as well as the rest of SA and eventually SSA. Targeted 
discussions were held between the biorepository leadership and the 
stakeholders, ethics officers and regulatory officials at various steps 
of biobank development.
The biobank currently has full HREC approval from the Faculty 
of Medicine and Health Sciences at Stellenbosch University and 
Tygerberg Academic Hospital, the tertiary academic hospital 
of Stellenbosch University. Meetings with most of the clinical 
departments pertinent to HIV malignancies have been held. The 
SSA RBR nurses have been trained as research nurses, and they 
request informed consent from patients identified by clinicians. The 
inventory is growing, and the first request for biospecimens (by an 
African investigator) has occurred. All requests for biospecimens 
will be vetted by an independent research evaluation and decision 
panel composed of experts identified by the NCI, including one or 
two representatives from Africa. Final approval for dispersal of ACSR 
biospecimens lies with the ACSR executive committee, in which the 
director of the SSA RBR is a member.
The SSA RBR director has begun outreach to other hospitals 
in Cape Town and the surrounding areas to raise the awareness 
of clinicians, scientists and junior investigators of the existence of 
the biobank. This effort involves meeting with clinical heads and 
pathologists from each hospital, and presenting the ACSR mission 
and the operation logistics envisioned for collaborating sites. In 
this scenario, the SSA RBR will work with the site to produce a 
standard operating procedure for informed consent and collection 
and transport of the specimen and data to the SSA RBR. Appropriate 
support will be supplied in the form of personnel needed for consent 
and collection, a pathologist for verification of diagnosis, and 
transport. These actions go towards the long-range plan for the SSA 
RBR to eventually house inventory from all of SSA.
Conclusion
The SSA RBR is a resource to benefit researchers, patients and 
communities in Africa. It offers numerous advantages, including 
operation under accepted best practices in biorepository management, 
with quality management in governance, personnel, operations and 
safety. It furthermore offers an opportunity to monitor trends 
in biospecimen research from an African perspective. Through 
collaboration with other institutions in SSA, the SSA RBR creates 
an opportunity to develop unique specimen collections and clinical 
data sets to promote multi-institutional collaborative research in the 
field of HIV-related cancers. The SSA RBR serves as a site for future 
National Institutes of Health/NCI cancer activities in Africa.
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